Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2014
08/28/2014WO2014130810A1 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
08/28/2014WO2014130809A1 Immobilized ligands for the removal of metal ions and methods thereof
08/28/2014WO2014130776A1 Phosphaplatins as neuroprotective agents
08/28/2014WO2014130759A1 Methods of using histamine receptor agonists and antagonists
08/28/2014WO2014130746A1 Use of an omega-3 lipid-based emulsion for protecting human organs from ischemic injury
08/28/2014WO2014130728A1 Norrin mutant polypeptides, methods of making and uses thereof
08/28/2014WO2014130720A1 Sensor for detecting analytes
08/28/2014WO2014130693A1 Inhibitors of bruton's tyrosine kinase
08/28/2014WO2014130678A2 Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction
08/28/2014WO2014130648A1 Method for treatment of pulmonary fibrosis
08/28/2014WO2014130638A1 Combinations of indigo naturalis and berberine and uses thereof
08/28/2014WO2014130619A2 Methods and compositions for treating leukemia
08/28/2014WO2014130608A1 Antidiabetic bicyclic compounds
08/28/2014WO2014130572A1 Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
08/28/2014WO2014130565A1 Substituted diaryl azetidine derivatives as sphingosine receptor modulators
08/28/2014WO2014130553A2 Tablet dosage forms
08/28/2014WO2014130550A1 Substituted diaryl derivatives as sphingosine receptor modulators
08/28/2014WO2014130534A1 Tricyclic heterocycles as anticancer agents
08/28/2014WO2014130526A1 Methods for treatment of atopic dermatitis and inflammatory skin disorders
08/28/2014WO2014130488A1 Functionalized nanoparticles for medical treatments
08/28/2014WO2014130470A1 Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
08/28/2014WO2014130411A1 Tgf-beta enhancing compositions for cartilage repair and methods related thereto
08/28/2014WO2014130398A1 Benzylamine containing compositions and methods for appetite suppression
08/28/2014WO2014130375A1 Heteroaromatic compounds as pi3 kinase modulators
08/28/2014WO2014130310A1 Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
08/28/2014WO2014130258A1 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
08/28/2014WO2014130068A1 Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs
08/28/2014WO2014130016A1 Drug combinations to treat liver cancer
08/28/2014WO2014129990A1 1 -(dimethylamino)ethyl-substituted 6h-benzo[c]chromen-6-ones against senile dementia
08/28/2014WO2014129989A1 3-substituted-6h-benzo[c]chromen-6-ones and 3-substituted-7,8,9,10-tetrahydro-6h-benzo[c]chromen-6-ones against senile dementia
08/28/2014WO2014129796A1 Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
08/28/2014WO2014129744A1 Four-membered cyclic nitrogen compound, pharmaceutical composition for preventing or treating depression, mental disorders, premature ejaculation or neuropathic pain, containing same, and preparation containing pharmaceutical composition
08/28/2014WO2014128728A2 Solid forms of cabazitaxel and processes for preparation thereof
08/28/2014WO2014128724A1 Antitubercular compounds and process for the preparation thereof
08/28/2014WO2014128661A1 Oral formulation and suspension of an oncology drug
08/28/2014WO2014128655A1 Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
08/28/2014WO2014128639A1 Composition for the treatment of metabolic disorders
08/28/2014WO2014128628A1 Cytoplasmic expression of fab proteins
08/28/2014WO2014128622A1 Quinazolines as kinase inhibitors
08/28/2014WO2014128612A1 Quinazolin-4-one derivatives
08/28/2014WO2014128611A1 Treatment of graft versus host disease in transplant patients
08/28/2014WO2014128591A1 Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
08/28/2014WO2014128588A1 Solid forms of a selective cdk4/6 inhibitor
08/28/2014WO2014128585A1 Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
08/28/2014WO2014128549A1 Novel ampk activator
08/28/2014WO2014128538A1 A process for the preparation of amoxicillin trihydrate
08/28/2014WO2014128524A1 An improved process for preparation of an intermediate of the pyrrolidine substituted flavones
08/28/2014WO2014128523A1 A process for preparation of an intermediate of the pyrrolidine substituted flavones
08/28/2014WO2014128486A1 Pyrimidine compounds useful in the treatment of diseases mediated by ikke and/or tbk1 mechanisms
08/28/2014WO2014128465A1 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
08/28/2014WO2014128289A1 Biomedical device implantable in bone and/or cartilaginous tissue, and corresponding method to manufacture said biomedical device
08/28/2014WO2014128259A1 Pharmaceutical composition for the treatment of burnout syndrome
08/28/2014WO2014128245A1 Dna hypomethylating agents for cancer therapy
08/28/2014WO2014128240A1 Inhibitors of na(v) 1.9 channel activity and uses thereof for treating pain
08/28/2014WO2014128233A1 Oral steroid formulations for use in the treatment of intestinal fibrosis
08/28/2014WO2014128225A1 Activation of inkt cells
08/28/2014WO2014128223A1 Pyridine derivatives as 5-ht6 receptor antagonists
08/28/2014WO2014128213A1 Compounds for use in inhibiting hiv capsid assembly
08/28/2014WO2014128209A1 Pharmaceutical formulation comprising dpp-iv inhibitor agglomerates
08/28/2014WO2014128206A1 Compounds for use in inhibiting hiv capsid assembly
08/28/2014WO2014128198A1 Bilaterally-substituted tricyclic compounds for the treatment of human immunodeficiency virus type-1 (hiv-1) infection and other diseases
08/28/2014WO2014128189A1 2-aminopyrimidine derivatives for the treatment of viral infections
08/28/2014WO2014128188A1 Anthranilamide compounds, their mixtures and the use thereof as pesticides
08/28/2014WO2014128116A1 A production process for gliclazide formulations
08/28/2014WO2014128109A1 Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
08/28/2014WO2014128093A1 Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
08/28/2014WO2014128079A1 Glatiramer acetate multidose formulation
08/28/2014WO2014128057A1 Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections
08/28/2014WO2014127816A1 Dihydropteridinones ii
08/28/2014WO2014127815A1 Dihydropteridinones i
08/28/2014WO2014127802A1 Stable compositions of bendamustine
08/28/2014WO2014127786A1 Orally disintegrating pharmaceutical composition comprising asenapine
08/28/2014WO2014127479A1 Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
08/28/2014WO2014127475A1 Therapeutic composition for the treatment perianal disorders
08/28/2014WO2014127459A1 Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines
08/28/2014WO2014127458A1 Pharmaceutical composition for transmucosal administration of benzodiazepines
08/28/2014WO2014127418A1 Conjugate compound and uses of same
08/28/2014WO2014113427A3 Irciniastatin analogues
08/28/2014WO2014107531A3 Desensitizing drug products containing lidocaine, thymol and ethanol
08/28/2014WO2014100418A3 Orally disintegrating tablet formulation for enhanced bioavailability
08/28/2014WO2014096425A3 Prodrugs of monomethyl fumarate (mmf)
08/28/2014WO2014083582A3 Novel process for the preparation of (1s,3ar,6as)-2-[(2s)-2-({(2s)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-n-[(3s)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c] pyrrole-1-carboxamide and its intermediates
08/28/2014WO2014082027A3 Antioxidant dietary supplement
08/28/2014WO2014081821A3 Small Molecule Bicyclic and Tricyclic CFTR Correctors
08/28/2014WO2014081343A3 Pharmaceutical composition containing nalbuphine hydrochloride, use thereof to treat moderate to severe pain and method for producing said pharmaceutical composition
08/28/2014WO2014066613A3 Sphingolipid metabolite mimetics
08/28/2014WO2013182998A4 Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes
08/28/2014WO2013138568A8 Liver x receptor modulators
08/28/2014WO2013134288A9 Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
08/28/2014US20140243765 Percutaneously absorbable preparation containing fentanyl and homologue thereof
08/28/2014US20140243764 Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systems
08/28/2014US20140243577 Combined Organ and Hematopoietic Cells For Transplantation Tolerance of HLA Mismatched Grafts
08/28/2014US20140243513 Methods for the Production of 3-O-Deactivated-4'-Monophosphoryl Lipid A (3D-MLA)
08/28/2014US20140243425 Controlled release compositions for modulating free-radical induced damage and methods of use thereof
08/28/2014US20140243422 Methods of treating behavioral and psychiatric disorders
08/28/2014US20140243420 Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids
08/28/2014US20140243419 Mucosally-applied agent for prevention, amelioration or treatment of retinal disease
08/28/2014US20140243418 Rasagiline for parkinson's disease modification
08/28/2014US20140243416 Topical Antiandrogen Therapy for the Treatment of Becker's Nevus
08/28/2014US20140243415 Compounds inhibiting galectin-1 expression, cancer cell proliferation, invasion, and tumorigenesis
1 ... 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 ... 7860